Precision BioSciences, Inc. (DTIL) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2024
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, Precision BioSciences, Inc. (DTIL) trades at a price-to-earnings ratio of 4.0x, with a stock price of $4.20 and trailing twelve-month earnings per share of $-7.07.
The current P/E is 68% below its 5-year average of 12.6x. Over the past five years, DTIL's P/E has ranged from a low of 2.4x to a high of 19.5x, placing the current valuation at the 33th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, DTIL trades at a 83% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, DTIL trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our DTIL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. RNA and Genome Editing Developers peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ALNYAlnylam Pharmaceuticals, Inc. | $44B | 142.9 | -Best | +207% |
SLXNWSilexion Therapeutics Ltd. | $64M | 0.0Lowest | -Best | +6436%Best |
DTILPrecision BioSciences, Inc. | $51M | 4.0 | -Best | +107% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | $3.81 | $1.62 | 2.4x | -81% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $8.96 | $0.46 | 19.5x | +55% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $9.73 | $0.61 | 16.0x | +27% |
Average P/E for displayed period: 12.6x
See DTIL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DTIL Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare DTIL vs AGIO
See how DTIL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is DTIL stock overvalued or undervalued?
DTIL trades at 4.0x P/E, below its 5-year average of 12.6x. At the 33th percentile of historical range, the stock is priced at a discount to its own history.
How does DTIL's valuation compare to peers?
Precision BioSciences, Inc. P/E of 4.0x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is DTIL's PEG ratio?
DTIL PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2024.